
In one of the most incredible single-day moves this year, biotechnology stock uniQure (NASDAQ: QURE) surged by 284% on Sept. 24. This came as the firm released fantastic clinical results for its developmental medicine, AMT-130.
With such a massive spike, uniQure is turning the heads of Wall Street analysts. Most still see upside, implying a high-risk, high-reward opportunity for investors.